Current role of cabozantinib in metastatic castration-resistant prostate cancer.

about

Contemporary approaches for imaging skeletal metastasis New therapeutic targets for cancer bone metastasis An overview of quinoline as a privileged scaffold in cancer drug discovery.

P2860

Q26798170-9FD36FB4-F17E-45F4-840B-22A056E65599 Q38473066-DA7608D0-A36F-4555-BBDF-6F1EDD8B501F Q39235281-6F13BF03-B765-4246-9ABC-966B23D67329

P2860

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q38317384

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

@en

type

Item

label

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

@en

prefLabel

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

@en

P1476

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

@en

P2093

André P Fay

http://www.w3.org/2001/XMLSchema#string

Joaquim Bellmunt

http://www.w3.org/2001/XMLSchema#string

Laurence Albiges

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Abiraterone in metastatic prostate cancer without previous chemotherapy

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Cancer treatment and survivorship statistics, 2014

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

P304

151-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2015.1003047

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laurence Albiges

P577

2015-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25586337

http://www.w3.org/2001/XMLSchema#string

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

about

P2860

P2860

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698